Description

Clidinium is a quaternary ammonium anticholinergic agent, primarily recognized for its potent antimuscarinic and antispasmodic properties. This compound is of significant commercial and therapeutic interest due to its specific action on smooth muscle, making it a critical active pharmaceutical ingredient (API). It is essential for manufacturers in the pharmaceutical industry, particularly those developing and producing gastrointestinal medications, antispasmodic formulations, and combination therapies for conditions like irritable bowel syndrome.

Application

• Pharmaceutical API: Primary use as the active ingredient in prescription antispasmodic and antisecretory medications.
• Gastrointestinal Therapeutics: Formulation into tablets, capsules, or combination drugs for treating abdominal cramps, spasms, and irritable bowel syndrome (IBS).
• Anticholinergic Agent: Used in pharmacological preparations to inhibit muscarinic acetylcholine receptors, reducing smooth muscle contractions and secretions.
• Combination Drug Synthesis: Often combined with other agents, such as benzodiazepines (e.g., Chlordiazepoxide), for enhanced therapeutic effect in specific treatment protocols.
• Research & Development: Serves as a reference standard and key intermediate in pharmaceutical R&D for new anticholinergic compounds.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of finished dosage forms.

Basic Information

Product Name	Clidinium
CAS No.	7020-55-5
Molecular Formula	C22H26ClNO3
Molecular Weight	387.90 g/mol
Synonyms	Clidinium Bromide (common salt form); 3-Hydroxy-1-methylquinuclidinium bromide benzilate; Quarzan; (3-Hydroxy-1-methylquinuclidinium) benzilate bromide; 1-Methyl-3-hydroxyquinuclidinium bromide benzilate; Librax (combination drug); 7020-55-5 (CAS); Clidinium cation
EINECS	230-304-5

Quality Control

Our Clidinium is manufactured under strict quality management systems to ensure it meets the stringent requirements for pharmaceutical actives. Each batch is subjected to comprehensive analytical testing, including identification, purity assay, and impurity profiling, to confirm compliance with in-house specifications and relevant pharmacopeial guidelines. A Certificate of Analysis (COA) detailing all test results is provided with every shipment to guarantee traceability and consistency.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). Keep the container tightly sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 1.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.